4 - Scilex Holding Co (0001820190) (Issuer)

4 - Scilex Holding Co (0001820190) (Issuer)

4 - Scilex Holding Co (0001820190) (Issuer)

4 - Scilex Holding Co (0001820190) (Issuer)

4 - Scilex Holding Co (0001820190) (Issuer)

3 - Scilex Holding Co (0001820190) (Issuer)

3 - Scilex Holding Co (0001820190) (Issuer)

3 - Scilex Holding Co (0001820190) (Issuer)

3 - Scilex Holding Co (0001820190) (Issuer)

3 - Scilex Holding Co (0001820190) (Issuer)

PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp

SAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), who is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that Elizabeth Czerepak will join the company as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective May 18, 2022. Ms. Czerepak will be a member of the Scilex and Sorrento Executive Leadership Teams, reporting to Scilex's Chief Executive Officer and President, Jaisim Shah, and Sorr

PALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors. Ms. Hamill brings to the Scilex board more than three decades of experience in the biopharma industry, serving most recently as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc. Prior to

SEC declared Effectiveness of Vickers's registration statement on Form S-4Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on November 9, 2022, at 10:00 a.m., Eastern TimePost-closing company will be renamed "Scilex Holding Company" upon closing of the Business Combination, with common stock and warrants expected to trade on the Nasdaq Capital Market under the new ticker symbols "SCLX" and "SCLXW", respectively.Closing of Business Combination can provide up to approximately $100 million of gross cash proceeds in the trust (assuming no redemptions by Vickers Vantage shareholders and before expenses assoc

PALO ALTO, Calif. and SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it pre-emptively paid off and eliminated all of its remaining Notes in an aggregate principal amount of $67.7 million for a cash payment of approximately $39.7 million. Scilex is a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))). Scilex Holding Company and Vickers Vantage Corp. I (NASDAQ:VCKA) ("Vickers"), a special purpose acquisi

SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data needed to support drug approval.Eligibility for Accelerated Approval or Priority Review, if relevant criteria are met.Rolling Review, which means that Scilex can submit completed sections of its New Drug Application (NDA) for review by the FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. Despite an overall lack of evidence to support their efficacy, opioids continue to be prescribed to trea

PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the signing of a Product Distribution Agreement ("Agreement") for certain designated territories with CH Trading Group LLC ("CH Trading"), an international import, export and trading company focused on the Middle East and North Africa (MENA) Region and other markets, to distribute Scilex's lead non-opioid commercial pain management product, ZTlido®. Scilex is a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (

30 million lives now covered by one of the largest national PBMsContinue to work with this PBM to access an additional 20 million livesThe team continues to work with the national PBM's and health plans to improve access further during 2022 with a goal to reach 250 million to 260 million lives in a covered or better position for ZTlido® PALO ALTO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), announced that, effective September 1, 2022, ZTlido® (lidocaine topical system) 1.8% will be added to one of the largest national PBMs and a national health plan – thereby expanding coverage

PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp

Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults.Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment market is large and projected to be $8.3 billion in the US by 2025 and has a compound annual growth rate of 16% with a well-defined area of unmet need.Scilex is well-positioned to market and distribute Gloperba: Scilex has a direct distribution network to national and regional wholesalers and pharmacies throughout all US states.Scilex has a very experienced commercial and managed care team that has successfully launched

SAN DIEGO and PALO ALTO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that on June 3, 2022, it pre-emptively paid off and eliminated $41.4 million of the principal amount of its senior secured notes (the "Notes"). In connection with this payoff, the holders of the Notes agreed that Scilex can repurchase the remaining principal amount of the Notes at any time on or before September 30, 2022 for

Earlier this year, a national pharmacy benefit manager (PBM) moved a large percentage of its patients from not covered to covered, adding access to ZTlido for 5.5 million lives. ZTlido is now covered by managed health care plans representing approximately 190 million of the over 300 million covered lives across the United States1. PALO ALTO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced

Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% in subjects with moderate to severe acute lower back pain (LBP). The trial will enroll 80 patients with acute lower back pain.SP-103 is a pharmacologically validated drug candidate and has the potential as a best-in-class agent of pain treatment for low back pain without the limitations of current therapies, including the addictive potential of opioids.An estimated 65 million adults in the U.S., or 25% of U.S. adults, suffer from acute low back pain1 with a total potential global market opportun

SC 13D/A - Scilex Holding Co (0001820190) (Subject)

SC 13D - Scilex Holding Co (0001820190) (Subject)

SC 13D/A - Scilex Holding Co (0001820190) (Subject)

SC 13D/A - Scilex Holding Co (0001820190) (Subject)

SC 13D/A - Scilex Holding Co (0001820190) (Subject)

SC 13G/A - Scilex Holding Co (0001820190) (Subject)

SC 13D/A - Scilex Holding Co (0001820190) (Subject)

SC 13G/A - Scilex Holding Co (0001820190) (Subject)

SC 13D - Scilex Holding Company/DE (0001820190) (Subject)

SC 13G/A - Vickers Vantage Corp. I (0001820190) (Subject)

  On Monday, 160 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: Atlassian (NASDAQ:TEAM) was the biggest company in terms of market cap to set a new 52-week low. The smallest company in terms of market cap to set a new 52-week low was Kalera (NASDAQ:KAL). Inhibikase Therapeutics (NASDAQ:IKT)'s stock came under the most pressure, trading down 35.35% to reach a new 52-week low. Kuke Music Holding (NYSE:KUKE) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low. The following stocks created new 52-week lows on Monday: Atlassian (NASDAQ:TEAM) shares hit a yearly low of $114.11. The stock was down 6.06% on the session

SEC declared Effectiveness of Vickers's registration statement on Form S-4 Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on November 9, 2022, at 10:00 a.m., Eastern Time Post-closing company will be renamed "Scilex Holding Company" upon closing of the Business Combination, with common stock and warrants expected to trade on the Nasdaq Capital Market under the new ticker symbols "SCLX" and "SCLXW", respectively. Closing of Business Combination can provide up to approximately $100 million of gross cash proceeds in the trust (assuming no redemptions by Vickers Vantage shareholders and before expens

Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the signing of a Product Distribution Agreement (“Agreement”) for certain designated territories with CH Trading Group LLC (“CH Trading”), an international import, export and trading company focused on the Middle East and North Africa (MENA) Region and other markets, to distribute Scilex’s lead non-opioid commercial pain management product, ZTlido®. Scilex is a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, &ldquo, Sorrento&rdquo, ))). “Our Agreeme

Ancora Medical Inc. ("Ancora") is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain management during the pre-operative, perioperative and post-operative periods associated with general and orthopedic surgery. The device allows physicians to locate peripheral nerves by transferring electrical impulses from a nerve stimulator and/or through ultrasound visualization of the device. The catheter may remain in dwelling for up to 72 hours. The global continuous peripheral nerve block catheter market is estimated to surpass $740.7 million by 2027.1 The global needle market will reach $8.4

Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% in subjects with moderate to severe acute lower back pain (LBP). The trial will enroll 80 patients with acute lower back pain. SP-103 is a pharmacologically validated drug candidate and has the potential as a best-in-class agent of pain treatment for low back pain without the limitations of current therapies, including the addictive potential of opioids. An estimated 65 million adults in the U.S., or 25% of U.S. adults, suffer from acute low back pain1 with a total potential global market op

Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM). There is a clear medical need for new, safe and effective treatments with the potential to improve care for the estimated 10 million FM patients in the U.S. and more than 200 million worldwide Phase 1 clinical trial data showed that SP-104 treated healthy volunteers and had lower rates of adverse events, as compared with immediate release naltrexone -treated volunteers.   PALO ALTO, Calif. and SAN DIEGO, May

Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that it will be presenting SP-102 (SEMDEXA™) efficacy and safety data from its Pivotal Phase 3 clinical C.L.E.A.R trial program (Corticosteroid Lumbosacral Epidural Analgesia for Radiculopathy) for sciatica pain management at the 24th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP) on May 5, 2022 in Las Vegas, NV.   The podium presentation will describe the

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies.   Cardinal 3PL will continue to provide trad

Scilex Holding Company ("Scilex"), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that it has entered into a non-binding term sheet with B. Riley Principal Capital, LLC ("BRPC"), a subsidiary of B. Riley Financial, Inc. (NASDAQ:RILY, together with its affiliates, ", B. Riley", ))))) for a committed equity financing facility (the "Facility") under which it would be able to sell up to $5 billion of its registered common stock over a five-year period. The Facility would become effective in connect